PubRank

D P Bolognesi

Author PubWeight™ 254.18‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1986 8.48
2 Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A 1988 7.74
3 Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A 1989 6.58
4 A novel murine oncornavirus with dual eco- and xenotropic properties. Proc Natl Acad Sci U S A 1975 5.91
5 Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci U S A 1986 5.55
6 A proposed nomenclature for the virion proteins of oncogenic RNA viruses. Virology 1974 5.01
7 Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A 1986 4.68
8 Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990 4.43
9 Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol 1988 4.13
10 Association of viral reverse transcriptase with an enzyme degrading the RNA moiety of RNA-DNA hybrids. Nat New Biol 1971 3.95
11 Assembly of type C oncornaviruses: a model. Science 1978 3.53
12 Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A 1987 3.47
13 Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997 3.35
14 A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol 1995 3.11
15 Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 1997 3.02
16 Localization of RNA tumor virus polypeptides. I. Isolation of further virus substructures. Virology 1973 2.94
17 Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci U S A 1987 2.53
18 Ribonucleic acid components of BAI strain A (myeloblastosis) avian tumor virus. Cancer Res 1967 2.53
19 Polypeptides of avian RNA tumor viruses. 1. Isolation and physical and chemical analysis. Virology 1970 2.49
20 Isolation of the major viral glycoprotein and a putative precursor from cells transformed by avian sarcoma viruses. Proc Natl Acad Sci U S A 1974 2.15
21 Polypeptides of avian RNA tumor viruses. IV. Components of the viral envelope. Virology 1972 2.09
22 Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA 1994 2.05
23 The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1992 2.00
24 A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. Proc Natl Acad Sci U S A 1987 1.87
25 Neutralization of homologous and heterologous oncornaviruses by antisera against the p15(E) and gp71 polypeptides of Friend murine leukemia virus. Virology 1976 1.73
26 Evidence that a precursor glycoprotein is cleaved to yield the major glycoprotein of avian tumor virus. J Virol 1977 1.70
27 Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc Natl Acad Sci U S A 1987 1.70
28 Isolation of proteins by gel filtration in 6M guanidinium chloride: application to RNA tumor viruses. Anal Biochem 1974 1.70
29 Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol 1990 1.68
30 Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis 1993 1.67
31 Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines. J Exp Med 1988 1.67
32 CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Res Hum Retroviruses 1993 1.66
33 An analysis of type-C retrovirus polypeptides and their associations in the virion. Virology 1978 1.65
34 Comparative chemical properties of avian oncornavirus polypeptides. Virology 1975 1.64
35 Polypeptides of mammalian oncornaviruses. II Characterization of murine leukemia virus polypeptide (p 15) bearing interspecies reactivity. Virology 1975 1.63
36 Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J Immunol 1989 1.63
37 Polypeptides of mammalian oncornaviruses. I. Isolation and serological analysis polypeptides from murine and feline C-type viruses. Virology 1973 1.59
38 HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J Immunol 1989 1.57
39 Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. J Virol 1998 1.57
40 Purification and serological characterization of the major envelope glycoprotein from AKR murine leukemia virus and its reactivity with autogenous immune sera from mice. J Virol 1976 1.56
41 Expression of murine leukemia virus structural antigens on the surface of chemically induced murine sarcomas. Proc Natl Acad Sci U S A 1974 1.54
42 Polypeptides of avian RNA tumor viruses. V. Analysis of the virus core. Virology 1972 1.51
43 Polypeptides of mammalian oncornaviruses. III. Localization of p 15 and reactivity with natural antibody. Virology 1975 1.48
44 Expression of the Major Viral Glycoprotein of Avian Tumor Virus in Cells of chf(+) Chicken Embryos. J Virol 1975 1.48
45 Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci U S A 1987 1.46
46 Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J Virol 1998 1.43
47 Biological, immunological, and biochemical evidence that HIX virus is a recombinant between Moloney leukemia virus and a murine xenotropic C type virus. Virology 1978 1.42
48 Macrophage accumulation in mice is inhibited by low molecular weight products from murine leukemia viruses. J Immunol 1980 1.41
49 Isolation and characterization of two group-specific antigens from feline leukemia virus. Virology 1971 1.41
50 Identification of human T cell leukemia virus in a Japanese patient with adult T cell leukemia and cutaneous lymphomatous vasculitis. Proc Natl Acad Sci U S A 1983 1.41
51 Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet 1988 1.38
52 Structural components of rna tumor viruses. Adv Virus Res 1974 1.37
53 Oncogenic and immunogenic potential of cloned HIX virus in mice and cats. Med Microbiol Immunol 1977 1.37
54 Polypeptides of avian RNA tumor viruses. II. Serological characterization. Virology 1970 1.32
55 Response of bone marrow to MC29 avian leukosis virus in vitro. Cancer Res 1969 1.30
56 Polypeptides of mammalian oncornaviruses. IV. Structural components of murine leukemia virus released as soluble antigens in cell culture. Virology 1975 1.30
57 GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody. J Immunol 1989 1.29
58 Changes in bioactive lipids, alkylacylglycerol and ceramide, occur in HIV-infected cells. Biochem Biophys Res Commun 1992 1.29
59 Group-specific antigenic determinants of the large envelope glycoprotein of avian oncornaviruses. Virology 1975 1.29
60 Structural rearrangements in the transmembrane glycoprotein after receptor binding. Immunol Rev 1994 1.29
61 In vitro chick embryo cell response to strain MC29 avian leukosis virus. J Virol 1968 1.26
62 Isolation of a transplantable cell line induced by the MC29 avian leukosis virus. Cancer Res 1974 1.25
63 Immunological properties of avian oncornavirus polypeptides. Virology 1975 1.25
64 Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J Immunol 1990 1.24
65 Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob Agents Chemother 1992 1.24
66 The ability of certain SIV vaccines to provoke reactions against normal cells. Science 1992 1.22
67 Ribosomal RNA in avian leukosis virus particles. Int J Cancer 1971 1.22
68 Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 1990 1.21
69 Inactivation of murine xenotropic oncornavirus by normal mouse sera is not immunoglobulin-mediated. Virology 1976 1.19
70 Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. J Virol 1998 1.18
71 Binding site for human immunodeficiency virus coat protein gp120 is located in the NH2-terminal region of T4 (CD4) and requires the intact variable-region-like domain. Proc Natl Acad Sci U S A 1988 1.17
72 Viral glycoprotein synthesis under conditions of glucosamine block in cells transformed by avian sarcoma viruses. Virology 1975 1.15
73 Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarifications. Science 1991 1.14
74 HIV fusion and its inhibition. Antiviral Res 2001 1.13
75 Properties of mouse leukemia viruses. II. Isolation of viral components. Virology 1972 1.10
76 AIDS. Where has HIV been hiding? Nature 1993 1.09
77 Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV. J Exp Med 1984 1.08
78 Mitosis is required for production of murine leukemia virus and structural proteins during de novo infection. J Virol 1975 1.08
79 Frog oocytes synthesize and completely process the precursor polypeptide to virion structural proteins after microinjection of avian myeloblastosis virus RNA. Proc Natl Acad Sci U S A 1977 1.08
80 Immunologic control of the ascites form of murine adenocarcinoma 755. V. Antibody-directed macrophages mediate tumor cell destruction. J Immunol 1981 1.07
81 Role of carbohydrate in determining the immunochemical properties of the major glycoprotein (gp71) of Friend murine leukemia virus. J Virol 1975 1.06
82 An ultrastructural study of C-type virion assembly in mouse cells. Cancer Res 1974 1.05
83 Strain MC29 avian leukosis virus release by chick embryo cells infected with the agent. Proc Soc Exp Biol Med 1969 1.03
84 Studies on the reproductive and cell-converting abilities of avian sarcoma viruses. Virology 1971 1.03
85 Structure and morphogenesis of type-C retroviruses. Adv Cancer Res 1978 1.02
86 Morphological and biochemical properties of a new human breast cancer cell line. Cancer Res 1979 1.02
87 NIH conference. HIV vaccine development: a progress report. Ann Intern Med 1994 1.02
88 Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III). Cancer Res 1985 1.01
89 Immunologic control of the ascites form of murine adenocarcinoma 755. IV. Characterization of the protective antibody in hyperimmune serum. J Immunol 1981 1.01
90 In vitro assays for detecting neutralizing and fusion-inhibiting antibodies to SIVMAC251. AIDS Res Hum Retroviruses 1991 1.01
91 Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. AIDS Res Hum Retroviruses 2000 1.00
92 Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res Hum Retroviruses 1992 1.00
93 Mammalian C-type oncornaviruses: relationships between viral structural and cell-surface antigens and their possible significance in immunological defense mechanisms. Contemp Top Immunobiol 1977 1.00
94 Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages. J Virol 1991 1.00
95 Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. J Immunol 1993 1.00
96 Influence of antisera to oncornavirus glycoprotein (gp71) on infections of cats with feline leukemia virus. Virology 1978 1.00
97 The initial nucleotide sequence of DNA transcribed from avian myeloblastosis virus 70 S RNA by RNA-dependent DNA polymerase. Virology 1975 0.99
98 Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. J Virol 1994 0.99
99 Relationships between membrane antigens of human leukemic cells and oncogenic RNA virus structural components. J Exp Med 1976 0.98
100 Further characterization of the oncornavirus inactivating factor in normal mouse serum. Virology 1979 0.98
101 Properties of mouse leukemia viruses. XVII. Factors required for successful treatment of spontaneous AKR leukemia by antibodies against gp71. Virology 1981 0.98
102 AIDS. Do antibodies enhance the infection of cells by HIV? Nature 1989 0.97
103 Biochemical properties of oncornavirus polypeptides. Biochim Biophys Acta 1974 0.96
104 Virus-infected avian cell lines established in vitro. Cancer Res 1976 0.94
105 Role of carbohydrate in biological functions of Friend murine leukemia virus gp71. J Virol 1977 0.94
106 Properties of mouse leukemia viruses. XIII. Serum therapy of virus-induced murine leukemias. Virology 1976 0.94
107 Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41. AIDS Res Hum Retroviruses 2000 0.93
108 Development of a vaccine for the prevention of AIDS, a critical appraisal. Vaccine 1992 0.93
109 Antibody reacting with mouse mammary tumor virus in serum of breast carcinoma patients. Surg Forum 1976 0.93
110 Two levels of restriction by mouse or cat cells of murine sarcoma virus coated by endogenous xenotropic oncornavirus. J Gen Virol 1975 0.92
111 Characterization of the immune response to the major glycoprotein (gp 71) of Friend leukemia virus. I. Response in BALB/c mice. Virology 1976 0.92
112 HIV vaccines. Viral envelope fails to deliver? Nature 1998 0.90
113 The structural polypeptides of equine infections anemia virus. Intervirology 1978 0.90
114 Interspecies reactivity of type C and D retrovirus p 15E and p 15C proteins. Virology 1981 0.90
115 Viral glycoprotein synthesis studies in an established line of Japanese quail embryo cells infected with the Bryan high-titer strain of Rous sarcoma virus. J Virol 1976 0.89
116 Effect of interferon on murine leukemia virus infection. II. Synthesis of viral components in exogenous infection. Virology 1977 0.89
117 Antibody-dependent cytolysis (ADCC) of tumor cells by activated murine macrophages is a two-step process: quantification of target binding and subsequent target lysis. Cell Immunol 1984 0.89
118 Detection of HIV-1 neutralizing antibodies by a simple, rapid, colorimetric assay. AIDS Res Hum Retroviruses 1988 0.89
119 IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). Clin Exp Immunol 1995 0.89
120 Properties of mouse leukemia viruses. XVI. Suppression of spontaneous fetal leukemias in AKR mice by treatment with broadly reacting antibody against the viral glycoprotein gp 71. Virology 1979 0.89
121 Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors. J Natl Cancer Inst 1985 0.88
122 Immunofluorescent analysis of expression of the RNA tumor virus major glycoprotein, gp71, on surfaces of virus-producing murine and other mammalian species cell lines. Cancer Res 1977 0.88
123 Toward a vaccine against AIDS: rationale and current progress. Mt Sinai J Med 1986 0.87
124 HTLV-III seroconversion associated with heat-treated factor VIII concentrate. Lancet 1986 0.87
125 Properties of mouse leukemia viruses. XIV. Prevention of spontaneous AKR leukemia by treatment with group-specific antibody against the major virus gp71 glycoprotein. Virology 1977 0.87
126 XVIII. Effective treatment of AKR leukemia with antibody to gp7 1 eliminates the neonatal burst of ecotropic AKR virus producing cells. Virology 1982 0.86
127 Inhibitory proteins in the Newcastle disease virus-induced suppression of cell protein synthesis. J Bacteriol 1966 0.86
128 Isolation of two subgroup-specific leukemogenic viruses from standard avian myeloblastosis virus. J Virol 1975 0.85
129 Immunologic control of a retrovirus-associated murine adenocarcinoma. VII. Tumor cell destruction by macrophages and IgG2A. J Natl Cancer Inst 1985 0.85
130 Prospects for the immunological management of lethal tumors. Cancer Invest 1983 0.85
131 Immunofluorescent analysis of expression of the RNA tumor virus major glycoprotein, gp71, on the surfaces of normal murine cells. Cancer Res 1977 0.85
132 Secretory immune response in patients with oropharyngeal carcinoma. Ann Otol Rhinol Laryngol 1983 0.84
133 Immunologic control of the ascites of murine adenocarcinoma 755. I. Protection with syngeneic immune serum or lymphoid cells. J Natl Cancer Inst 1978 0.84
134 The effects of leukemosuppressive immunotherapy on bone marrow infectious cell centers in AKR mice. Virology 1987 0.84
135 BAI strain A avian (myeloblastosis) leukosis virus from myeloblast tissue culture. Proc Soc Exp Biol Med 1966 0.84
136 Cellular immune response to viral peptides in patients exposed to HIV. AIDS Res Hum Retroviruses 1988 0.84
137 Multiple CTL specificities against autologous HIV-1-infected BLCLs. Cell Immunol 1995 0.84
138 Detection of a transformation-specific glycopeptide in SSV-infected cells. Virology 1981 0.83
139 A determination of the outer dimensions of oncornaviruses by several electron microscopic procedures. Cancer Res 1974 0.83
140 The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals. Cell Immunol 1991 0.83
141 Size differences among the high molecular weight RNA's of avian tumor viruses. Virology 1971 0.82
142 Noncytolytic CD8 T cell-mediated suppression of HIV replication. Springer Semin Immunopathol 1997 0.82
143 [Morphogenesis and structure of RNA tumor viruses. Electron microscopy studies on C-type viruses]. Zentralbl Bakteriol Orig A 1972 0.82
144 Immunologic control of a retrovirus-associated murine adenocarcinoma. VI. Augmentation of antibody-dependent killing following quantitative and qualitative changes in host peritoneal cells. J Natl Cancer Inst 1985 0.82
145 Response of the secretory immune system to bronchogenic carcinoma of the lung. Surg Forum 1979 0.82
146 Interspecies determinants of Friend leukemia virus antigens involved in cytolysis of virus-pfoducing cells. J Virol 1977 0.81
147 The role of bone marrow and thymic elements in the initiation and spread of virus production in the AKR thymus. Virology 1988 0.81
148 The coenrichment of stem cells, prothymocytes, and stromal elements with ecotropic retrovirus-producing cells from the bone marrow of leukemia-prone AKR mice. Virology 1988 0.81
149 Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. AIDS Res Hum Retroviruses 1994 0.80
150 Minor RNA and other components of host origin intrinsic to avian leukosis virus particles. Bibl Haematol 1970 0.80
151 [Stimulation of immunoreactivity against endogenous retroviruses and protection against leukemia in aged AKR mice after vaccination with antibodies to viral surface components. The role of antibodies to p15(E)]. Z Naturforsch C 1985 0.80
152 Detection of the major glycoproteins of Friend leukemia virus (gp71) and the murine mammary tumor virus (gp52) on the surface of mouse cells. Cancer Res 1976 0.79
153 Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy. Trans Assoc Am Physicians 1993 0.79
154 Immunologic control of the ascites form of murine adenocarcinoma 755. III. Efficacy of serum therapy is controlled by a single genetic locus. J Immunol 1981 0.79
155 HIV immunization. Fresh pathways to follow. Nature 1990 0.79
156 HIV infection in vaccinated volunteers. JAMA 1994 0.79
157 Immunotherapy of a murine leukemia virus-infected, chemically induced murine sarcoma with antiviral antibodies. J Natl Cancer Inst 1982 0.79
158 Properties of mouse leukemia viruses. XIX. Effective antibody therapy of AKR leukemia occurs independently of virus neutralization and produces long-term changes in the virus status of the thymus. Virology 1984 0.78
159 Prospects for development of a vaccine against HTLV-III-related disorders. AIDS Res Hum Retroviruses 1987 0.78
160 Outer membrane of avian myeloblastosis virus. J Virol 1973 0.78
161 Specificity and distribution of the determinants of the major glycoprotein (gp71) of murine oncornaviruses as detected by an in vitro cytotoxicity assay. J Natl Cancer Inst 1977 0.78
162 Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein. Haematol Blood Transfus 1987 0.78
163 Polypeptides of endogenous avian C-type viruses: their detection in the plasma membrane of normal and infected cells. Virology 1977 0.78
164 Reactivity of avian RNA tumor viruses with lectins. J Virol 1975 0.78
165 Comparison of anti-HIV-1 ADCC reactivities in infected humans and chimpanzees. J Acquir Immune Defic Syndr 1994 0.78
166 Transfer of radioiodine from iodinated oncornavirus proteins to unlabeled protein carrier during routine procedures for peptide mapping. Biochem Biophys Res Commun 1977 0.78
167 Human leukemia antigens: partial isolation and characterization. J Natl Cancer Inst 1974 0.78
168 Human T-cell leukemia/lymphoma virus: studies of host-virus interaction. Curr Top Microbiol Immunol 1985 0.78
169 Characterization of the immune response to the major glycoprotein (gp71) of Friend leukemia virus. II. Response in C57BL/6 mice. Virology 1976 0.77
170 Polypeptides of mammalian oncornaviruses. II. Characterization of a murine leukemia virus polypeptide (p15) bearing interspecies reactivity. Virology 1975 0.77
171 Elevated serum secretory immunoglobulin A levels in patients with head and neck carcinoma. Otolaryngol Head Neck Surg 1983 0.77
172 Morphological, chemical, and antigenic organization of mammalian C-type viruses. Bibl Haematol 1975 0.77
173 A model for assembly of type-c oncornaviruses. Med Microbiol Immunol 1977 0.77
174 AIDS vaccines: progress and unmet challenges. Ann Intern Med 1991 0.76
175 Prospects for treatment of human retrovirus-associated diseases. Cancer Res 1985 0.76
176 Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs. J Surg Res 1998 0.76
177 In vivo antigenic modification of tumor cells. III. Metastatic thymic lymphoma specifically infected by thymotropic retrovirus. J Natl Cancer Inst 1981 0.75
178 In vivo antigenic modification of tumor cells. I. Introduction of murine leukemia virus antigens on non-virus-producing murine sarcomas. J Natl Cancer Inst 1981 0.75
179 Synthesis and complete processing of a high-molecular-weight precursor polypeptide to viral structural proteins in toad oocytes micro-injected with avian myeloblastosis virus ribonucleic acid [proceedings]. Biochem Soc Trans 1977 0.75
180 Immunodeficiency. Curr Opin Immunol 1995 0.75
181 A procedure for the preferential radioiodination of small amounts of protein in the presence of excess lipids. Anal Biochem 1979 0.75
182 Loss of tumorigenicity following in vitro MuLV infection is associated with induction of peritoneal natural killer cell activity. Adv Exp Med Biol 1988 0.75
183 Translation of 35S RNA from avian myeloblastosis virus into viral specific polypeptides in Xenopus oocytes. Arch Int Physiol Biochim 1976 0.75
184 Structural components of avian myeloblastosis virus. Bibl Haematol 1973 0.75
185 Polypeptides of avian RNA tumor viruses. 3. Purification and identification of a DNA synthesizing enzyme. Virology 1971 0.75
186 Antigenic relationships between murine, feline and primate RNA tumor viruses and membrane antigens of human leukemic cells. Bibl Haematol 1975 0.75
187 Cross-reactions of virally and chemically induced mouse sarcomas: surface expression of a common viral antigen. Surg Forum 1975 0.75
188 Immuno-prophylaxis and -therapy of C-type oncorna viral diseases in mice and cats. Med Microbiol Immunol 1977 0.75
189 Immunodeficiency. Curr Opin Immunol 1994 0.75
190 In vivo antigenic modification of tumor cells. II. Distribution of virus in sarcoma-bearing mice. J Natl Cancer Inst 1981 0.75
191 Mammalian C-type oncorna viruses. Relationships between structural virus and cell surface antigens and their possible significance in immunological defense mechanisms. Bibl Haematol 1975 0.75
192 AIDS vaccines. Sci Am 1988 0.75
193 A single genetic locus determines the efficacy of serum therapy against murine adenocarcinoma 755a. Haematol Blood Transfus 1979 0.75
194 Clonal isolate of the simian sarcoma virus codes for a Gag-related 65,000-dalton protein. Virology 1981 0.75
195 Retroviruses and human cancer: evaluation of T-lymphocyte transformation by human T-cell leukemia-lymphoma virus. Cancer Invest 1985 0.75
196 Association of the viral reverse transcriptase with an enzyme degrading the RNA moiety of RNA-DNA hybrids. Bibl Haematol 1973 0.75
197 The effects of leukemosuppressive immunotherapy on thymic infectious cell centers in AKR mice. Thymus 1989 0.75
198 Characterization of the immune response to the major glycoprotein (gp71) of Friend leukemia virus. III. Influence on endogenous MuLV-mediated pathogenesis. Virology 1976 0.75
199 Potential leukemia virus subunit vaccines: discussion. Cancer Res 1976 0.75
200 [Chicken RNA tumor viruses: a model for virus-induced carcinogenesis]. Zentralbl Bakteriol Orig A 1972 0.75
201 Murine in vitro antigenic modification of tumor cells: effect on susceptibility to natural cell-mediated cytotoxicity. J Natl Cancer Inst 1985 0.75
202 Immunologic control of the ascites form of murine adenocarcinoma 755. II. Tumor immunity associated with a Friend--Moloney--Ra,scher-type virus. J Natl Cancer Inst 1978 0.75
203 Structure and specific antigens of avian leukosis viruses. Bibl Haematol 1970 0.75
204 Summary of session on oncornaviruses I. Virus-cell interactions and virus structure analyses. Bibl Haematol 1975 0.75
205 Function of the secretory immune system in bronchogenic carcinoma. Immunoglobulin A levels in respiratory secretions. J Thorac Cardiovasc Surg 1981 0.75
206 AZT inhibits HIV-1 replication in monocytes. J Acquir Immune Defic Syndr 1988 0.75